TBL Drugs

TBL Drugs - Drug Ins ulin MOA Tolbutam ide Glipizide Nate...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Drug MOA Adverse Effects Insulin - Act through RTK receptors (P13Kinase and MAPK pathways) - Membrane bound receptor Tolbutamide - 1 st generation sulfonylurea - 2 nd generation sulfonylurea **these two no to type I (no beta cells) - Non- sulfonylurea insulin secretogogue - DEC K+ (ATP) Channel in beta cells [ need beta cells to function!] - Depolarizes cell - Ca++ comes into cell exocytosis - Do not give to TYPE I because no beta cells! - Risk of hypogalcemia (due to insulin release) - Weight gain (salt/water retention) Glipizide Nateglinide Exenatide - Incretin mimetic (GLP-1 agonist Gs-R) - INC cAMP PKA Ca++ open more enhance glucose mediated insulin secretion [[ INC glucose mediated insulin secretion (b-cells) ]] - DEC glucagon (alpha cells) - DEC appetite - DEC gastric emptying all lead to DEC DEC Glucose - GLP-1 is released in the GI tract to help the glucose load (supportive hormone) - Pancreatitis (abdomen pain or vomiting) - Weight loss Pramlintide (Symlin) ** type I & II -
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 09/14/2011 for the course PHARM TBL taught by Professor Staff during the Spring '11 term at UCSD.

Page1 / 3

TBL Drugs - Drug Ins ulin MOA Tolbutam ide Glipizide Nate...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online